Novel thiosemicarbazone and thiazolidin‐4‐one derivatives containing vanillin core: Synthesis, characterization, and anticancer activity studies
Feyzi Sinan Tokalı, Halil Şenol, Tuğba Gençoğlu Katmerlikaya, Aydan Dağ, Kıvılcım Şendil
Abstract
Abstract Cancer is one of the most common and lethal disease in the world, therefore, patients need new and potent anticancer agents for treatment. In this study, starting from vanillin, 24 new compounds, which are 12 thiosemicarbazone (4a‐h, 5i‐j, 6k) and 12 thiazolidin‐4‐one ( 7a‐h, 8i‐j and 9k) derivatives, were synthesized and characterized by Nuclear Magnetic Resonance (NMR), High‐Resolution Mass Spectroscopy (HRMS), and Fourier‐transform Infrared (FTIR) techniques. In vitro cytotoxic effects were investigated on CCD‐1079Sk human healthy fibroblast and MDA‐MB‐231 human breast cancer cell lines. For MDA‐MB‐231, molecules showed IC 50 in ranging of 88.08 ± 0.027–16.54 ± 0.031 μM (Doxorubicin: 61.70 ± 0.021 μM) and for CCD‐1079Sk, molecules showed IC 50 in ranging of 192.36 ± 0.018–13.58 ± 0.035 μM (Doxorubicin:52.01 ± 0.028 μM). Compounds 6k and 7f were found most selective and potent anticancer agents compared to Doxorubicin used as a standard drug.